限制谱成像评分作为前列腺癌定量生物标志物:阳性预测值可靠
本研究在7个中心评估了基于扩散MRI的限制谱成像限制评分(RSIrs)对临床显著前列腺癌(csPCa,GG≥2)的患者级检测性能。在877例活检初治患者中,RSIrs的AUC为0.73,显著优于ADC(0.54,P<.01),与PI-RADS(0.75)相当(P=.31);RSIrs联合PI-RADS优于任一单独使用,且RSIrs联合PI-RADS、年龄和PSA密度区分度最佳。
要点
- RSIrs是一种客观定量生物标志物,无需影像学专家经验即可估计csPCa概率。
- 在活检初治患者中,RSIrs的AUC显著优于ADC,与PI-RADS相当。
- RSIrs联合PI-RADS、年龄和PSA密度可达到最佳的csPCa区分度。
核心结论
- RSIrs是一种准确可靠的定量生物标志物,对患者级csPCa检测性能优于传统ADC,与专家定义的PI-RADS相当。
- RSIrs可提供无需放射学专业知识的客观csPCa概率估计。
研究设计与样本
- 多中心研究,7个中心,参与者于2016年1月至2024年3月接受前列腺MRI。
- 纳入符合标准患者n=1892,其中活检初治患者n=877。
主要发现
- 在活检初治患者(n=877)中,区分GG≥2 vs 非csPCa的AUC:RSIrs=0.73(0.69-0.76),ADC=0.54(0.50-0.57),PI-RADS=0.75(0.71-0.78)。
- RSIrs显著优于ADC(P<.01),与PI-RADS相当(P=.31)。
- RSIrs与PI-RADS联合优于任一单独使用。
- RSIrs、PI-RADS、年龄和PSA密度联合模型对csPCa区分度最佳。
临床怎么用
- RSIrs可作为客观定量工具用于患者级csPCa风险分层,减少对放射学专家经验的依赖。
- 可考虑将RSIrs与PI-RADS、年龄和PSA密度联合使用以提高csPCa检测区分度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The positive predictive value of the Prostate Imaging Reporting and Data System (PI-RADS) for clinically significant prostate cancer (csPCa, grade group [GG] ≥2) varies widely between radiologists. The restriction spectrum imaging restriction score (RSIrs) is a biophysics-based metric derived from diffusion MRI that could be an objectively interpretable biomarker for csPCa. We aimed to evaluate performance of RSIrs for patient-level detection of csPCa in a large and heterogenous dataset, and to combine RSIrs with clinical and imaging parameters for csPCa detection. MATERIALS AND METHODS: At 7 centers, participants underwent prostate MRI between January 2016 and March 2024. We calculated patient-level csPCa probability based on maximum RSIrs in the prostate and compared patient-level csPCa detection to apparent diffusion coefficient (ADC) and PI-RADS using AUC. We also evaluated csPCa discrimination by GG and combining RSIrs with clinical risk factors through multivariable regression. RESULTS: Among patients who met the inclusion criteria (n = 1892), probability of csPCa increased with higher RSIrs. Among biopsy-naïve patients (n = 877), AUCs for GG ≥ 2 vs non-csPCa were RSIrs = 0.73 (0.69-0.76), ADC = 0.54 (0.50-0.57), and PI-RADS = 0.75 (0.71-0.78). RSIrs significantly outperformed ADC (P < .01) and was comparable with PI-RADS (P = .31). RSIrs and PI-RADS combined outperformed either alone. The model with RSIrs, PI-RADS, age, and PSA density achieved the best discrimination of csPCa. CONCLUSIONS: RSIrs is an accurate and reliable quantitative biomarker that performs better than conventional ADC and comparably with expert-defined PI-RADS for patient-level detection of csPCa. RSIrs provides objective estimates of probability of csPCa that do not require radiology expertise.
引用
- Rojo Domingo M, Do DD, Conlin CC, et al. Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value. J Urol. 2025. PMID: 40377262. doi:10.1097/JU.0000000000004611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。